Wachovia Cuts EPS Estimates on ICN Pharma

Analyst Michael Tong suspects issues bigger than royalty problems at the drugmaker may be cause of its shortfall

Wachovia Securities cuts its estimates on ICN Pharmaceuticals (ICN ) after the company said it sees Q3 EPS from operations of $0.08 to $0.13.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.